Search
Tandem Diabetes Care Inc
TNDMAdd to Watchlist
19.500USD
+0.490+2.58%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.34BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Tandem Diabetes Care Inc is 7.39, ranking 142 out of 199 in the Healthcare Equipment & Supplies industry. The average price target is 18.00, with a high of 55.00 and a low of 14.00.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
28.974
Target Price
+48.58%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
109
Total
7
Median
9
Average
Company name
Ratings
Analysts
Tandem Diabetes Care Inc
TNDM
22
Medtronic PLC
MDT
34
Stryker Corp
SYK
32
Dexcom Inc
DXCM
32
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
29
1
2
3
...
22
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Tandem Diabetes Care Inc's expected revenue for the next quarter?
Tandem Diabetes Care Inc's expected revenue is 254.98M.
What is Tandem Diabetes Care Inc's price target?
Analysts forecast that Tandem Diabetes Care Inc's price target is USD 18.00, with the highest forecast at USD 55.00 and the lowest forecast at USD 14.00.
How have Tandem Diabetes Care IncTNDM's recent earnings per share performed?
The market expectation was USD -0.30, while Tandem Diabetes Care IncTNDM's earnings per share (EPS) for the previous quarter was USD -0.01. EPS for the next quarter is expected at USD -0.32.
What is the analyst rating for Tandem Diabetes Care Inc?
Based on the ratings of Tandem Diabetes Care Inc's stock from 22 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.